Abemaciclib
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer/ Metastatic Breast Cancer
Conditions
Breast Cancer/ Metastatic Breast Cancer
Trial Timeline
Dec 22, 2020 → Apr 1, 2025
NCT ID
NCT04681768About Abemaciclib
Abemaciclib is a pre-clinical stage product being developed by Eli Lilly for Breast Cancer/ Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04681768. Target conditions include Breast Cancer/ Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02792725 | Pre-clinical | Completed |
| NCT03763604 | Pre-clinical | Completed |
| NCT06025747 | Phase 1 | Recruiting |
| NCT06678269 | Phase 1 | Recruiting |
| NCT04003896 | Phase 2 | Terminated |
| NCT04408924 | Phase 2 | Completed |
| NCT04681768 | Pre-clinical | Completed |
| NCT03891784 | Phase 2 | Active |
| NCT03837821 | Phase 1 | Active |
| NCT03339843 | Phase 2 | Completed |
| NCT03703466 | Phase 2 | Completed |
| NCT03310879 | Phase 2 | Recruiting |
| NCT02919696 | Phase 1 | Completed |
| NCT03130439 | Phase 2 | Terminated |
| NCT02981940 | Phase 2 | Active |
| NCT02846987 | Phase 2 | Active |
| NCT02482935 | Phase 1 | Completed |
| NCT02308020 | Phase 2 | Completed |
| NCT02387814 | Phase 1 | Completed |
| NCT02102490 | Phase 2 | Completed |
Competing Products
20 competing products in Breast Cancer/ Metastatic Breast Cancer